Furthermore, inhibitors of the key nucleotide biosynthetic enzyme ribonucleotide reductase (RNR) can be re-deployed to alter the intracellular nucleotide pool and thereby indirectly suppress the intracellular ara-CTP hydrolysis activity of SAMHD1 in various models of AML,52 which is now being evaluated in a clinical trial.53 The gene discussed is SAMHD1; the disease is acute myeloid leukemia.